
In a close vote, an advisory panel for the U.S. Food and Drug Administration decided not to recommend the approval of an experimental drug for the deadly neurological disease amyotrophic lateral sclerosis (ALS). The panel’s decision had been closely watched, with patient advocacy groups lobbying hard for fast-track approval. However, on Wednesday the panel ruled… read on > read on >